Dr Cory Calendine Appointed to Osso VR Advisory Board

Orthopedic surgeon at Bone and Joint Institute of Tennessee joins Osso VR to advance global development and adoption of VR surgical training technology

Dr Cory Calendine, M.D., an orthopedic surgeon at the Bone and Joint Institute of Tennessee, has officially joined the Osso VR Clinical Advisory Board.

Dr Cory Calendine’s extensive experience in arthroplasty and advanced surgical technologies provides Osso VR and its executive team a valuable resource to accelerate the development of the company’s leading surgical training platform.

Dr. Calendine is a board-certified orthopaedic surgeon specializing in both traditional and robotic total joint arthroplasty. He received his medical degree from the University of Tennessee College of Medicine, completed a residency in orthopaedic surgery at Vanderbilt University Medical Center, and did his fellowship training in adult reconstruction of the hip and knee at the world-renowned Anderson Orthopaedic Research Institute in Alexandria, Virginia.
“I am humbled and honored to be joining the Osso VR advisory board. Osso VR is on the cutting edge of surgical training technology and is producing world-changing technology at a truly global scale. In addition, the team has such a warm, fun-loving culture.  At the end of the day, I was drawn not just to their technology and culture, but also to their mission of democratizing global access to the latest surgical techniques, something that I am extremely passionate about and proud to be a part of.” said Dr. Cory Calendine, M.D.
Osso VR’s surgical training technology provides on-demand, immersive experiences that are effective, repeatable, and measurable to help surgeons reach proficiency with new procedures and devices. The platform has become integral to surgical training programs worldwide and is currently used by thousands of surgeons each month in 20+ leading teaching hospitals and over 15 top medical device companies in over 20 countries.
“I’ve admired the work of Dr. Calendine for years, and I am humbled that he’s joined our advisory board team to continue driving our technology and VR surgical adoption throughout the globe. Innovation in healthcare is not just about developing new technology but also how you communicate about that technology. Dr. Calendine is reshaping the way we are thinking about communication partially through his innovative use of social media to educate healthcare professionals and the public on the value of emerging medical technologies.” said Justin Barad, MD, CEO and co-founder of Osso VR. “Dr. Calendine not only brings his unique expertise to Osso VR, but he also has a passion for democratizing healthcare which is a core part of our mission.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”